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ABSTRACT: DNA transposases catalyze the movement of
transposons around genomes by a cut-and-paste mechanism
related to retroviral integration. Transposases and retroviral
integrases share a common RNaseH-like domain with a catalytic
DDE/D triad that coordinates the divalent cations required for
DNA cleavage and integration. The anti-retroviral drugs
Raltegravir and Elvitegravir inhibit integrases by displacing viral
DNA ends from the catalytic metal ions. We demonstrate that
Raltegravir, but not Elvitegravir, binds to Mos1 transposase in the
presence of Mg2+ or Mn2+, without the requirement for transposon
DNA, and inhibits transposon cleavage and DNA integration in
biochemical assays. Crystal structures at 1.7 Å resolution show
Raltegravir, in common with integrases, coordinating two Mg2+ or
Mn2+ ions in the Mos1 active site. However, in the absence of transposon ends, the drug adopts an unusual, compact binding
mode distinct from that observed in the active site of the prototype foamy virus integrase.
Transposons and viruses are mobile genetic elements thatsurvive and propagate by integrating into their hosts’
genomes. DNA transposons are cut out from one genomic
location and pasted into another by a DNA transposase, often
encoded within the transposon sequence. This genetic
rearrangement provides a driving force for genomic variation
and evolution but can also generate genomic instability. Some
transposons have become domesticated within their host’s
genome and provide useful new functions: for example the
V(D)J recombination system, which generates antibody
diversity, and the methyltransferase-DNA transposase fusion
protein SETMAR involved in DNA repair.1,2
The mechanism of DNA transposition is closely related to
the integration of retroviruses, such as human immunodeﬁ-
ciency virus 1 (HIV-1). DNA transposases speciﬁcally
recognize short inverted repeat (IR) sequences that mark the
transposon ends. Excision of the transposon and its integration
at a new genomic site is coordinated within a nucleoprotein
complex, the transpososome, in which the two transposon ends
are paired. Likewise, viral DNA ends contain long terminal
repeat (LTR) sequences that are recognized speciﬁcally by a
retroviral integrase and are brought together in a nucleoprotein
complex, the intasome. The integrase cleaves two nucleotides
from the reactive DNA strand before joining the processed viral
ends irreversibly to the host’s genome.
The mechanistic similarities of DNA transposases and
retroviral integrases are reﬂected in common active site
architectures and similar structural features.3,4 The catalytic
core domains of these enzymes adopt a RNase-H like fold5
bringing together a triad of catalytic acidic amino acids: the
DDE/D motif. The carboxylate oxygens coordinate the Mg2+ or
Mn2+ ions required for DNA cleavage and integration.6 A
number of crystal structures of isolated catalytic core domains
of DNA transposases and integrases have been determined:
these include the active mariner family transposase Mos1 (from
Drosophila mauritiana7), the closely related mariner transposase
catalytic domain of SETMAR (human8), and the retroviral
integrase HIV-19,10 (shown in Figure 1). Furthermore there are
crystal structures of the Mos1,11 Tn5,12 and Mu13 trans-
pososomes and the Spumavirus Prototype Foamy Virus (PFV)
intasome,14 each of which contains the full length enzyme in a
synaptic complex with two cognate DNA ends.
The Mos1 and human SETMAR mariner transposases show
a higher degree of structural similarity compared with integrases
(Figure 1 and Supplementary Figure 1). The active sites of
HIV-1 and PFV integrase contain DD-35-E motifs, whereas the
mariner family DNA transposase Mos1 active site has a DD-34-
D triad. The SETMAR mariner transposase catalytic domain
has a DD-34-N motif, which supports DNA cleavage and
integration,15,16 and shares 38.7% sequence identity and 48.4%
sequence similarity to Mos1. In all four enzymes the loop
preceding the third catalytic residue contains conserved Tyr
and Pro residues; these are Try276 and Pro278 in Mos1
Transposase (Tnp). In the Mos1 Tnp and SETMAR catalytic
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domain crystal structures, this loop is ordered due to its
stabilizing interactions with the N- and C-terminal capping
helices, α1 and α7 respectively (Figure 1). As a result the active
sites are fully structured without DNA. By contrast, in the
crystal structure of the isolated HIV-1 integrase catalytic core
domain,10 the loop was disordered. NMR relaxation measure-
ments indicated that loop residues are dynamic, moving
between several distinct conformational clusters.17 This is
consistent with the proposal that the integrase active site does
not adopt a well-deﬁned conformation, capable of binding
divalent metal ions and inhibitor, until the integrase has
assembled on viral ends.18
The DNA integration step of the retroviral life cycle has been
targeted for the development of anti-retroviral therapies.
Currently, several integrase strand transfer inhibitors (INSTIs)
are available or in development for the treatment of HIV-1
infections, including Raltegravir19 and Elvitegravir.20 Attempts
to crystallize the HIV-1 integrase with viral DNA ends have so
far been unsuccessful, and surrogate models have been sought
in order to better understand how INSTIs act. The Tn5
transposase was considered as a model system, because of the
wealth of structural information on its interactions with
inverted repeat DNA. Several diketoacid HIV-1 integrase
inhibitors were identiﬁed using Tn5 transposase as the target
in a chemical library screen;21 these aﬀected cleavage, synapsis,
or integration steps of Tn5 transposition.22 More recently, the
PFV integrase, a closer relative of the HIV-1 enzyme, has
provided an amenable model system.23−25 Co-crystal structures
of the PFV intasome with Raltegravir or Elvitegravir revealed
that the drugs inhibit viral DNA integration by coordinating
two divalent metal ions bound to the DDE motif carboxylates
and displacing the reactive viral DNA end from the active
site.14,26
Recently it was shown that Raltegravir and Elvitegravir can
also inhibit the nuclease activity of the transposase domain
within the human fusion protein SETMAR.27 We asked if
Raltegravir and Elvitegravir could bind to and inhibit the DNA
cleavage and integration activities of Mos1,28 an active mariner
family transposase closely related to the transposase domain of
SETMAR.2 Here we show that Raltegravir binds to Mos1
transposase and that divalent metal ions, but not transposon IR
DNA, are required for binding. By contrast Elvitegravir did not
bind to Mos1 Tnp. We have determined crystal structures of
Raltegravir bound in the active site of the Mos1 Tnp catalytic
domain in the presence of Mg2+ or Mn2+, to a resolution of 1.7
Å. The drug adopts a distinct, compact, and curved binding
mode that contrasts markedly with the conformation of the
drug in the viral DNA-bound PFV intasome structures.
Furthermore, Raltegravir inhibits Mos1 in vitro DNA cleavage
and integration. Our structural results for Mos1-Raltegravir
interactions can potentially be used as a surrogate model for
development of drugs to target the transposase domain of
SETMAR. Inhibiting the DNA repair functions of SETMAR in
this way could be used to augment current chemotherapies.
■ RESULTS AND DISCUSSION
Mos1 Transposase Is Stabilized by Divalent Metal
Ions. In previous crystallographic analyses7 of the Mos1
Figure 1. The catalytic domains of mariner DNA transposases and retroviral integrases adopt a common Rnase-H like fold. Catalytic core domain
structures of (a) Mos1 transposase (PDB ID: 2F7T), (b) SETMAR transposase domain (PDB ID: 3K9J), (c) HIV-1 integrase (PDB ID: 1BIS), and
(d) PFV Integrase in the intasome complex (PDB ID: 3S3M). Residues of the DDD/N or DDE active site triads are labeled, along with the
coordinated metal ions and conserved Tyr and Pro residues.
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Figure 2. Thermal stability of Mos1 transposase. (a) Mos1 transposase is stabilized by MgCl2 and MnCl2. The melting temperature (Tm) and
standard deviations (s.d.) were calculated as the mean of three measurements. The chemical structures of (b) Raltegravir and (c) Elvitegravir from
http://www.chemspider.com. (d) Eﬀect of increasing Raltegravir or Elvitegravir concentrations on the Tm of Mos1 transposase. Reactions contained
20 mM MgCl2 or MnCl2 as indicated.
Table 1. X-ray Data Collection, Scaling, and Reﬁnement Statistics
crystal
Mos1 + Raltegravir (10 mM MgCl2 ) Mos1 + Raltegravir (10 mM MnCl2 )
PDB ID 4MDB 4MDA
space group P4(1)2(1)2 P4(1)2(1)2
cell dimensions a,b = 44.2, c = 206.3 Å a,b = 44.6, c = 209.6 Å
wavelength (Å) 0.9795 0.9795 1.8961
overall outer shell overall outer shell overall outer shell
resolution (Å) 44.2−1.7 1.8−1.7 43.6−1.7 1.79−1.7 43.6−2.13 2.25−2.13
Rmerge 0.065 0.302 0.071 0.248 0.066 0.138
total observations 129702 17666 166470 24181 106759 15206
unique observations 23539 3320 24487 3466 12671 1794
⟨I⟩/σ⟨I⟩ 14.5 4.7 16.7 6.6 21.9 13.0
completeness (%) 99.7 99.9 100.0 100.0 99.9 100.0
multiplicity 5.5 5.3 6.8 7.0 8.4 8.5
anomalous completeness (%) 99.9 100.0
anomalous multiplicity 4.6 4.5
Rwork 0.197 0.197
Rfree 0.241 0.242
rmsd from ideality
bond length (Å) 0.019 0.019
bond angle (deg) 2.08 2.05
chirality (Å) 0.232 0.259
Ramachandran plot
preferred (%) 97.9 96.7
allowed (%) 2.1 3.3
outliers (%) 0 0
av B factor (Å2) 25.7 19.6
no. of metal ions 2 2
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catalytic domain, we observed one metal ion bound in the
active site when 5 mM MgCl2 or MnCl2 was included in the
crystallization conditions; this was coordinated by the
carboxylate oxygen atoms of Asp 156 and Asp 249, in site 1.
When we increased the MnCl2 concentration to 20 mM, a
second Mn2+ was bound to Asp 156 and Asp 284, in site 2.7 To
establish the extent of stabilization of Mos1 Tnp by divalent
metal ions, we performed thermal denaturation assays29 to
determine the melting temperatures (Tm) of Mos1 Tnp at
diﬀerent metal ion concentrations (Figure 2a). In the absence
of divalent metal ions, the Tm of Mos1 Tnp was 40.5 °C. Upon
addition of MgCl2 or MnCl2 (5 mM, 20 mM or 50 mM) the Tm
increased by up to 10.0 °C to a maximum of 50.5 °C in 20 mM
MnCl2. These results reﬂect stabilization of transposase by the
metal ions. A concentration-dependent increase in transposase
thermal stability was observed for the Mg2+ series. The larger
increases in Tm measured with MnCl2, compared to equivalent
concentrations of MgCl2, indicate that Mn
2+ stabilizes Mos1
transposase to a greater extent than Mg2+.
Raltegravir Binds to Mos1 Transposase. Next, we
investigated the eﬀect of Raltegravir (Figure 2b) and
Elvitegravir (Figure 2c) on the thermal stability of Mos1
Tnp. Raltegravir (5 μM to 1 mM) or Elvitegravir (5 μM to 100
μM) was incubated with Mos1 (4 μM) in the presence or
absence of either MgCl2 (20 mM) or MnCl2 (20 mM). The
addition of 1 mM Raltegravir and 20 mM MnCl2 increased the
Tm of Mos1 Tnp to 61 °C (Figure 2d). However, Raltegravir
did not induce a change in the Tm in the absence of MgCl2 or
MnCl2. These data indicate that Raltegravir binds to Mos1 Tnp
and that the interaction requires divalent cations. By contrast,
Elvitegravir induced little or no change in the Tm of Mos1 Tnp,
suggesting there is no binding in the conditions tested.
Raltegravir Binds Mos1 in an Unusual Compact
Conformation. To establish the conformation of Raltegravir
bound to Mos1 transposase, we soaked crystals of the Mos1
transposase catalytic domain, grown in either 10 mM MgCl2 or
10 mM MnCl2, with 1 mM Raltegravir, as detailed in Methods.
Crystals diﬀracted X-rays to 1.7 Å resolution (Table 1), and
structures were determined by molecular replacement using the
structure of the Mos1 catalytic domain (PDBID: 2F7T) as the
model. The initial 2Fo − Fc map contained clear additional
electron density near the active site into which Raltegravir was
built. The structures were reﬁned to a ﬁnal Rfree of 24.1% and
24.2% for the structures containing Mg2+ and Mn2+,
respectively (Figure 3a−c, Table 1). We also collected
diﬀraction data from crystals grown in MnCl2 at the Mn K-
edge (λ = 1.896 Å, Table 1), and the peaks in an anomalous
diﬀerence map conﬁrmed the positions of the two Mn2+ ions in
the active site (Figure 3b).
Raltegravir adopts a compact, curved conformation in the
Mos1 active site (Figure 3a). The ﬂuorobenzyl ring is oriented
on the same side as the methyl-oxadiazole group and ﬁlls a
Figure 3. X-ray crystal structures of Raltegravir bound to the Mos1 transposase catalytic domain. (a) Active site of Mos1 transposase (blue) with
Raltegravir (green sticks) bound to Mn2+ ions (purple spheres). The omit map of electron density (green mesh) is contoured at 3σ. Water molecules
coordinated to the metal ions are displayed as red spheres. (b) Octahedral coordination of manganese ions in the active site, with anomalous
diﬀerence electron density map contoured at 2.5σ (pink mesh). (c) Active site of the magnesium ion bound structure, with magnesium ions shown
as black spheres. Conformations of Raltegravir bound to (d) Mos1 transposase catalytic domain and (e) the PFV intasome (PDB ID: 3OYA).
Rotation about the CBC−CBF bond (indicated by a black arrow) would interconvert these two conformations. (f) Conformation of Elvitegravir
bound to the PFV intasome (PDB ID: 3LSU).
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hydrophobic pocket on Mos1 Tnp lined by Ala 251 and Pro
252. The six-membered ﬂuorobenzyl ring tops a four-tiered
aromatic ring stack, which also includes the ﬁve-membered
oxadiazole moiety of Raltegravir and the side chains of Tyr 276
and His 122 of Mos1 Tnp (Figure 3a). In addition, the
Raltegravir isopropyl group makes hydrophobic contacts with
the conserved residue Pro 278. A similar “folded-over” binding
mode was predicted for Raltegravir docked in the HIV-1
integrase active site in the absence of viral DNA, using
computational methods.30
Our crystal structures show that the carboxylate side chains
of the active site aspartic acid triad coordinate two divalent
metal ions (Figure 3a−c). Three coplanar oxygen atoms of the
Raltegravir diketo acid moiety chelate Mg2+ or Mn2+ ions in the
active site, explaining the requirement for metal ions for drug
binding. The central oxygen, O(H), bridges both metal ions,
whereas O(E) coordinates the site 1 metal ion and O(G)
coordinates the metal ion in site 2 (Figure 3b,c). Both metal
ions exhibit octahedral coordination geometry. Coordination of
the site 1 metal ion is completed by monodentate interactions
with Asp 249 and Asp 156 side chains, with additional
coordinating atoms from two water molecules. The second
carboxylate oxygen of Asp 156 chelates the metal in site 2, and
the coordination geometry is completed by bidentate
interactions with the carboxylates of Asp 284 and one water
molecule.
Previously both Raltegravir and Elvitegravir were found to be
inactive against the Tc1 transposase Sleeping Beauty.31
Comparison of the sequences of Mos1 and Sleeping Beauty
transposases reveals that key residues of the Mos1 catalytic
domain that are involved in stacking interactions of the
Raltegravir oxidiazole group in our crystal structure are not
conserved in Sleeping Beauty transposase (Supplementary
Figure 1). These include Tyr 276, His 122, and Ala 251 in
Mos1, which are Gln 270, Pro 121, and Asp245 at the
equivalent positions in the Sleeping Beauty transposase
sequence. This suggests a molecular explanation for the
observed inability of Raltegravir and Elvitegravir to inhibit
Sleeping Beauty transposition.31
Raltegravir Has a Diﬀerent Binding Mode in Mos1
Tnp Compared with the PFV Intasome. The Mos1-bound
conformation of Raltegravir (Figure 3d) contrasts markedly
with its elongated conformation when bound to PFV integrase
with viral DNA ends14 (Figure 3e). In the PFV intasome bound
conformation, the ﬂuorobenzyl group is distant from the
oxadiazole group and occupies a tight pocket created by
displacement of the 3′ adenosine of the viral DNA strand where
it stacks with the penultimate base-pair of the viral DNA
duplex. Elvitegravir adopts a similar conformation when bound
to the PFV intasome (Figure 3f).
The two distinct conformations of Raltegravir bound to
Mos1 or the PFV intasome (Figure 3d−e) are related by a
rotation of ∼180° about the Raltegravir CBC−CBF bond, as
shown by the arrow in Figure 3e. This rotation ﬂips the
position of the ﬂuorobenzyl ring with respect to the oxadiazole
and isopropyl groups, which are in similar positions in both
structures. These groups make stacking and hydrophobic
interactions with the side chains of the conserved Tyr and
Pro loop residues in both binding modes: Tyr 276 and Pro 278
of Mos1 and Tyr 212 and Pro 214 of PFV integrase (Figure 4).
Rotation about the Raltegravir CBC−CBF bond also swaps
the relative positions of the three metal-chelating oxygen atoms.
However, their spatial arrangement is intact, enabling
coordination of the two divalent metal ions in the active site
of Mos1 transposase in a manner similar to that observed in the
PFV intasome co-crystal structures, despite the drug adopting a
distinctly diﬀerent conformation. Thus, the rotational freedom
within Raltegravir allows it to adopt a previously unappreciated
bound conformation, highlighting that a drug can have distinct
binding modes in subtly diﬀerent molecular environments.
The chemical structure of Elvitegravir (Figure 2c) is
inherently less ﬂexible than that of Raltegravir (Figure 2b),
and there is a diﬀerent separation of the three, rigidly coplanar
chelating oxygen atoms. It also lacks the oxadiazole group that
forms key stacking interactions in the Raltegravir-bound Mos1
structure. Taken together, these factors may explain our
observation that Elvitegravir did not bind to Mos1 transposase.
Raltegravir Binds to the Mos1 Paired-End Complex.
Mos1 transposase recognizes speciﬁc IR sequences at each
transposon end and brings them together in a paired-end
complex (PEC) for DNA cleavage, before inserting the cleaved
ends into TA dinucleotide sites on target DNA. To test if
Raltegravir could also interact with and inhibit Mos1 Tnp
bound to IR DNA, we ﬁrst performed thermal denaturation
assays using the Mos1 PEC. This complex was prepared using
‘precleaved’ IR DNA substrates as before.32 Similarly to Mos1
Tnp, the Mos1 PEC was stabilized by divalent metal ions
(Figure 5a); the stabilization was greater with 20 mM MnCl2
(Tm = 55.5 °C) than with 20 mM MgCl2 (Tm = 49 °C).
Raltegravir (100 or 400 μM) bound the Mos1 PEC in the
presence of Mg2+ or Mn2+, increasing the Tm up to a maximum
of 62.5 °C with 400 μM Raltegravir and 20 mM MnCl2. We
also tested if Elvitegravir could bind to the Mos1 PEC. A small
increase, of 1.75 °C, in the Tm of the Mos1 PEC in the presence
of 400 μM Elvitegravir and 20 mM MgCl2 indicated that
Elvitegravir may bind weakly in these conditions. However, no
change in thermal stability of the PEC was observed with
Figure 4. Comparison of the binding modes of Raltegravir in (a) the
active site of the Mos1 catalytic domain and (b) the PFV intasome.
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Elvitegravir in 20 mM MnCl2. Thus, Raltegravir binds to the
Mos1 PEC in the presence of divalent metal ions.
Raltegravir Inhibits Mos1 Cleavage and Strand Trans-
fer. To establish if Raltegravir or Elvitegravir inhibit the DNA
cleavage activity of Mos1 transposase, we performed a plasmid
cleavage assay.33 The 5.6 kb supercoiled plasmid contains Mos1
transposon IRs. After incubation with Mos1 transposase, ∼70%
of the supercoiled plasmid is relaxed or linearized by
transposase DNA cleavage (Figure 5b, lane 5). Mos1 cleavage
activity is inhibited by 10 to 500 μM Raltegravir (Figure 5b,
lanes 6−10) with an IC50 of 60−70 μM as estimated from
quantiﬁcation of the % of supercoiled plasmid in each reaction
(Figure 5c). By contrast, the addition of Elvitegravir over the
same concentration range (Figure 5d, lanes 5−9) had no
signiﬁcant eﬀect on Mos1 cleavage activity or the % of
supercoiled and open circle plasmid in each reaction (Figure
5e).
Next, we tested the eﬀect of Raltegravir on Mos1 strand
transfer by monitoring the integration of ﬂuorescently labeled,
precleaved transposon IR DNA substrates into a 50-mer target
DNA duplex containing one TA dinucleotide (Figure 6a).
Integration into the top or bottom strand of the target duplex
produces two major strand transfer products, of 68 and 40 nt,
respectively, which are then detected by denaturing PAGE
(Figure 6b, lane 3). Other minor products result from
integration into the IR DNA substrate, the sequence of which
contains two TA dinucleotides. When Raltegravir is added (in
the concentration range 1 to 100 μM), integration is inhibited
(Figure 6b, lanes 4−10) with an IC50 of ∼2 μM (Figure 6c).
This result implies that Raltegravir binds more tightly to the
Mos1 PEC than to the transposase in the absence of DNA. The
tighter binding could reﬂect additional interactions between
precleaved IR DNA and the drug and/or a diﬀerent Raltegravir
binding mode; a co-crystal structure of Raltegravir and the
Mos1 PEC would shed light on these possibilities.
Figure 5. Raltegravir stabilizes the Mos1 PEC and inhibits Mos1 cleavage in vitro. (a) The melting temperature (Tm) of the Mos1 PEC measured in a
thermal denaturation assay, without or with 20 mM MgCl2 or MnCl2, and in the absence or presence of Raltegravir or Elvitegravir at the
concentrations indicated. The Tm and standard deviations (s.d.) were calculated as the mean of three measurements. (b) Agarose gel of the products
of Mos1 IR plasmid cleavage reactions: without Mos1 transposase (lane 4), with Mos1 (lanes 5−10), and with increasing concentrations of
Raltegravir (lanes 6−10). Supercoiled (sc) and open circle (oc) plasmids are indicated, and supercoiled plasmid is shown in lane 3. The plasmid
linearized by restriction digestion is shown in lane 2. (c) Graph of the percentage of sc and oc plasmid in lanes 4−10 of the gel in panel b. (d)
Agarose gel of the products of Mos1 IR plasmid cleavage reactions; without Mos1 transposase (lane 3), with Mos1 (lanes 4−9), and with increasing
concentrations of Elvitegravir (lanes 5−9). (e) Graph of the percentage of sc and oc plasmid in lanes 3−9 of the gel in panel d.
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Both Raltegravir and Elvitegravir inhibit the in vitro DNA
cleavage activity of the human DNA repair component fusion
protein SETMAR,27 by binding to the active site of the mariner
transposase catalytic domain. SETMAR is overexpressed in
malignant cells34 (e.g., leukemia) and enhances the eﬃciency
and accuracy of DNA repair by non-homologous end-joining.2
It has been proposed that targeting the nuclease activity of
SETMAR with small molecules could augment current
chemotherapies27 by inhibiting DNA repair. We have shown
here that Raltegravir can also inhibit the in vitro DNA cleavage
and integration of the mariner transposase Mos1. Given the
wealth of structural and mechanistic understanding of the Mos1
DNA transposase and the close sequence and structural
similarities between Mos1 and the transposase domain of
SETMAR, the Mos1 transposase may provide an ideal model
system to aid the development of drugs to target SETMAR.
■ METHODS
Sequence Alignments. Structure-based sequence alignments of
the transposase and integrase catalytic domains were performed using
Expresso 35 and displayed using ESPript2.2.36
Puriﬁcation of Mos1 Transposase.Mos1 transposase containing
the solubilizing mutation T216A (referred to as Mos1 throughout)
was expressed and puriﬁed as previously described37 with some
changes. The protein was extracted from resuspended cells in a cell
disruptor (Constant Systems, Ltd.) at 27 kPsi. After cation exchange
chromatography of cleared lysate, the protein was further puriﬁed by
hydrophobic interaction chromatography. Ammonium sulfate was
added (to 1 M) before loading Transposase onto a HiTrap Phenyl HP
column (GE Healthcare). Transposase was eluted using a decreasing
ammonium sulfate gradient (1 to 0 M), then exchanged into 50 mM
Tris pH7.5, 0.35 M KCl, 1 mM DTT, and concentrated using a 6 mL
Vivaspin column (10 kDa cutoﬀ). The purity of the protein was
assessed by SDS-PAGE.
Annealing of IR DNA Duplex. Oligonucleotides were synthesized
by Integrated DNA Technologies and dissolved in water prior to
annealing. Duplex IR DNA containing the right inverted repeat
sequence and with a 3 base overhang, corresponding to an excised
transposon end, was prepared by annealing a 28-mer (5′-AAAC-
GACATTTCATACTTGTACACCTGA-3′) and a complementary 25-
mer (5′-GGTGTACAAGTATGAAATGTCGTTT-3′). For the target
integration assays the 28-mer had an IRDye 700 ﬂuorescent tag at the
5′ end.
Paired-End Complex Preparation. For paired-end complex
formation, transposase and duplex IR DNA were mixed in the molar
ratio 1 to 1.1, in buﬀer containing 25 mM Tris (pH 7.5) and 0.25 M
NaCl. The protein was added in 10 μL aliquots to the DNA and mixed
thoroughly between additions. Final concentrations of the PEC ranged
from 20 to 200 nM.
Thermal Denaturation Assays. The thermal stability of Mos1
transposase and the Mos1 PEC was measured in an iCycler IQ5 Real
Time Detection System (BioRad) thermal cycler. Each sample was
prepared to a ﬁnal volume of 50 μL in a 96-well plate and contained 4
μM puriﬁed Mos1 transposase or 6 μM PEC, 5x Sypro Orange (Sigma
Aldrich), 50 mM Tris pH 7.5, 0.35 M KCl, 1 mM DTT, and metal
ions (MgCl2 or MnCl2) at 0, 5, 20 or 50 mM. Thermal denaturation
was also performed with samples containing Raltegravir (at 5, 20, 100,
500 μM or 1 mM) or Elvitegravir (at 5, 20, or 100 μM) with 20 mM
MgCl2 or 20 mM MnCl2. Control reactions, containing 100 μM
Raltegravir or 100 μM Elvitegravir, without metal ions were also
measured.
Samples were heated from 20 to 80 °C in increments of 0.5 °C
every 30 s. The ﬂuorescence of Sypro Orange was excited at 485 nm
and measured at 575 nm in relative ﬂuorescence units (RFU). The
sensitivity of Sypro Orange to the hydrophobicity of the chemical
environment results in an increase in ﬂuorescence intensity as the
sample unfolds and hydrophobic residues are exposed. The transition
unfolding temperature (Tm) of each sample was taken as the minimum
value of the derivative −δRFU/δTemp. Each condition was measured
in triplicate and an average Tm for each condition calculated.
Crystallization and Crystal Soaks. Crystals of the Mos1 catalytic
domain were grown by hanging drop vapor diﬀusion as previously
described.37 Puriﬁed Mos1 transposase at 8 mg mL−1 was mixed in the
ratio 1:1 with well solution containing MgCl2 (5 mM) or MnCl2 (5
mM), 22% (w/v) PEG 4000, 100 mM Tris pH 6.8. Crystals appeared
after incubation at 290 K for 10 days. For soaking experiments, crystals
were transferred to a solution containing 10 mM MgCl2 or MnCl2,
22% (w/v) PEG 4000, 100 mM Tris pH 6.8, 20% (v/v) glycerol, and 1
Figure 6. Raltegravir inhibits Mos1 strand transfer. (a) Schematic of the strand transfer assay. (b) Denaturing polyacrylamide gel showing the eﬀect
of increasing concentrations of Raltegravir on strand transfer activity of Mos1 transposase. Lane 1 shows oligonucleotide markers of length indicated
to the left of the lane. The control reaction in lane 2 did not contain Mos1 transposase. (c) Graph of intensity of the product bands as a function of
Raltegravir concentration (band intensities are normalized to the intensity of the 40 nt product without Raltegravir).
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mM Raltegravir and incubated over the well solution for 18 h. Crystals
were then ﬂash frozen in liquid nitrogen prior to data collection.
Structure Determination and Reﬁnement. X-ray diﬀraction
data were collected at beamline I02 at the Diamond Light Source.
Images were collected on a ADSC Q315r detector, integrated with
iMosﬂm, and scaled using SCALA within the CCP4 suite.38 Phases
were calculated by molecular replacement in PHASER using the
coordinates of the Mos1 catalytic domain (PDB ID: 2F7T) as the
search model. Structure reﬁnement was performed with REFMAC and
the ﬁnal data collection and reﬁnement statistics are shown in Table 1.
Stereoviews of the ﬁnal Mg2+ (PDB ID: 4MDB) or Mn2+ (PDB ID:
4MDA) containing structures showing ﬁnal 2Fo − Fc electron density
maps are shown in Supplementary Figure 2 and Supplementary Figure
3, respectively.
Plasmid Cleavage Assays. Assays were performed in 20 μL
reactions containing 500 ng of plasmid pEPMosRR (containing a 1.3
kB Kanamycin resistance gene ﬂanked by Mos1 IRs, with a 4.3 kB
pEP185.2 backbone), 48 nM Mos1 transposase, 25 mM Hepes pH 7.5,
0.1 M NaCl, 10% (v/v) glycerol, 12.5 μg mL−1 acetylated BSA, 2 mM
DTT, and 10 mM MnCl2. Reactions were incubated at 30 °C for 20
min, stopped by the addition of EDTA to 10 mM, and separated on a
1% (w/v) agarose gel in 1x TAE buﬀer at 70 V for 2 h. DNA was
stained using SafeView (NBS Biologicals) and visualized and
quantiﬁed on a GelDoc EZImager (BioRad).
Target Integration Assays. A 50-mer target DNA substrate
containing one TpA dinucleotide was prepared by annealing the 50 nt
sequence 5′ AGCAGTCCACTAGTGCACGACCGTTCAAAGCT-
TCGGAACGGGACACTGTT with its complementary strand.
Annealed target and IR DNA oligonucleotides were puriﬁed by
HPLC. Assays were performed in 20 μL reactions containing 15 nM
50-mer target DNA, 1.5 nM IR DNA, and 15 nM Mos1 Transposase
in buﬀer containing 25 mM Hepes pH 7.5, 50 mM potassium acetate,
10% (v/v) glycerol, 0.25 mM EDTA, 1 mM DTT, 10 mM MgCl2, 50
μg mL−1 BSA, and 20% (v/v) DMSO. Raltegravir was added to
reactions as indicated. Reactions were incubated for 2 h at 30 °C, and
the products were separated on an 8% denaturing polyacrylamide gel
as described previously.11 To visualize the products, the IRDye 700
was excited at 680 nm and detected on a LI-COR Odyssey system.
The ﬂuorescence intensities of the product bands were quantiﬁed
using Image Studio software.
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